#1 Clinical Trials Search in Europe

Messenger Rna Encoding Cas9

This article explores recent clinical trials utilizing an innovative gene editing technology called CRISPR, specifically focusing on trials using messenger RNA encoding Cas9. These groundbreaking studies aim to treat various genetic disorders by directly editing problematic genes in patients. We’ll examine the potential of this approach for conditions like transthyretin amyloidosis, hemophilia B, alpha-1 antitrypsin deficiency, and hereditary angioedema.

Table of Contents

Introduction

MESSENGER RNA ENCODING CAS9 is an innovative gene therapy medication currently being studied for the treatment of several genetic conditions. This therapy, also known as ziclumeran or mRNA000042, is part of a new class of treatments that aim to edit genes directly inside the body to treat or potentially cure certain diseases[1].

Mechanism of Action

This therapy works by delivering genetic instructions (mRNA) to cells, which then produce the Cas9 protein. Cas9 is a key component of the CRISPR gene-editing system. When combined with a guide RNA (gRNA) specific to the target gene, Cas9 can make precise changes to DNA sequences[2].

The mRNA and gRNA are typically packaged in lipid nanoparticles (LNPs) to protect them and help them enter cells. Once inside, the cell’s machinery uses the mRNA to produce the Cas9 protein, which then works with the gRNA to make the desired genetic changes[3].

Conditions Being Studied

Clinical trials are currently investigating the use of MESSENGER RNA ENCODING CAS9 for several genetic conditions:

  • Transthyretin (ATTR) Amyloidosis: A condition where abnormal protein deposits build up in various organs, causing damage[1].
  • Hemophilia B: A blood clotting disorder caused by a deficiency in clotting factor IX[2].
  • Hereditary Angioedema (HAE): A rare genetic condition characterized by recurrent episodes of severe swelling[4].
  • Alpha-1 Antitrypsin Deficiency (AATD): A genetic disorder that can lead to lung and liver disease[5].

Administration and Dosage

MESSENGER RNA ENCODING CAS9 is typically administered as an intravenous infusion. The dosage varies depending on the specific condition being treated and the stage of research. In some trials, single doses ranging from 0.1 mg/kg to 55 mg have been studied[6].

Safety and Side Effects

As this is an experimental therapy, its full safety profile is still being established through clinical trials. Potential side effects being monitored include:

  • Infusion-related reactions
  • Changes in liver function tests
  • Immune system responses
  • Unintended effects on non-target genes

Patients receiving this treatment are closely monitored for any adverse events. Long-term follow-up studies are also being conducted to assess the therapy’s safety over time[3].

Ongoing Research

Several clinical trials are currently underway to evaluate the safety and efficacy of MESSENGER RNA ENCODING CAS9 for various conditions:

  • Phase 3 trials for ATTR Amyloidosis with cardiomyopathy[1]
  • Phase 1/2 trials for Hemophilia B[2]
  • Phase 1/2 trials for Hereditary Angioedema[7]
  • Phase 1/2 trials for Alpha-1 Antitrypsin Deficiency[5]

These studies are assessing various aspects of the treatment, including its ability to reduce disease symptoms, improve quality of life, and potentially provide long-term benefits with a single dose.

Conclusion

MESSENGER RNA ENCODING CAS9 represents a promising frontier in gene therapy. While still in the experimental stages, this approach has the potential to offer new treatment options for patients with certain genetic conditions. As research progresses, more information will become available about its effectiveness and long-term safety. Patients interested in this therapy should discuss the latest developments with their healthcare providers and consider the possibility of participating in clinical trials if appropriate.

Trial Focus Conditions Targeted Key Components Administration Primary Objectives
CRISPR Gene Editing Transthyretin Amyloidosis, Hemophilia B, Alpha-1 Antitrypsin Deficiency, Hereditary Angioedema Messenger RNA encoding Cas9, Single Guide RNA Single intravenous infusion Safety, tolerability, efficacy in reducing disease symptoms
Delivery Method All trials Lipid nanoparticle formulations Intravenous infusion Efficient delivery of gene editing components to target cells
Safety Monitoring All trials Adverse events, laboratory tests Throughout study period Assess short-term and long-term safety of gene editing treatment
Efficacy Measures Varies by condition Disease-specific biomarkers, symptom reduction Multiple timepoints post-treatment Evaluate therapeutic effect of gene editing on disease progression
Long-term Follow-up All trials Safety and efficacy assessments Extended observation periods Monitor durability of treatment effect and long-term safety

FAQ

  • What is CRISPR gene editing? CRISPR is a revolutionary gene editing technology that allows scientists to make precise changes to DNA. In these trials, it's being used to target and modify specific genes associated with genetic disorders.
  • How does messenger RNA encoding Cas9 work in gene therapy? Messenger RNA encoding Cas9 is used to deliver instructions for making the Cas9 enzyme, a key component of the CRISPR system. This enzyme acts like molecular scissors, allowing for precise editing of targeted genes.
  • What conditions are being targeted in these clinical trials? The trials are focusing on genetic disorders such as transthyretin amyloidosis, hemophilia B, alpha-1 antitrypsin deficiency, and hereditary angioedema.
  • Are these treatments administered once or multiple times? Most of these trials involve a single administration of the gene therapy, with the goal of providing long-lasting or permanent genetic correction.
  • What are the potential benefits of this approach compared to traditional treatments? This gene editing approach has the potential to address the root cause of genetic disorders, potentially offering long-term or permanent therapeutic effects with a single treatment, unlike many traditional therapies that require ongoing medication.

Ongoing Clinical Trials on Messenger Rna Encoding Cas9

  • Study on the Safety and Effectiveness of REGV131 and LNP1265 for Adults with Hemophilia B

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain

  • Study on the Safety of NTLA-3001 for Adults with Alpha-1 Antitrypsin Deficiency-Related Lung Disease

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Ireland

Glossary

  • CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats, a gene editing technology that allows for precise modifications to DNA.
  • Cas9: CRISPR-associated protein 9, an enzyme that acts like molecular scissors in the CRISPR gene editing system.
  • Messenger RNA (mRNA): A type of RNA that carries genetic information from DNA to the cell's protein-making machinery.
  • Transthyretin Amyloidosis: A rare genetic disorder characterized by the buildup of abnormal proteins in various organs, leading to organ dysfunction.
  • Hemophilia B: A genetic bleeding disorder caused by a deficiency in blood clotting factor IX.
  • Alpha-1 Antitrypsin Deficiency: A genetic disorder that can lead to lung and liver disease due to low levels of a protein called alpha-1 antitrypsin.
  • Hereditary Angioedema: A rare genetic condition characterized by recurrent episodes of severe swelling in various parts of the body.
  • Lipid Nanoparticle (LNP): A microscopic particle made of fats used to encapsulate and deliver genetic material into cells.
  • Single Guide RNA (sgRNA): A short RNA sequence that guides the Cas9 enzyme to the specific DNA location that needs to be edited.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical effects.
  • Pharmacokinetics (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.

References

  1. http://clinicaltrials.eu/trial/2023-507220-23-00/study-of-ntla-2001-for-patients-with-transthyretin-amyloidosis-and-heart-disease/
  2. http://clinicaltrials.eu/trial/2023-507260-40-00/study-on-the-safety-and-effectiveness-of-regv131-and-lnp1265-for-adults-with-hemophilia-b/
  3. http://clinicaltrials.eu/trial/2023-507385-11-00/long-term-safety-study-of-ntla-2001-for-patients-with-hereditary-transthyretin-amyloidosis-with-polyneuropathy-or-transthyretin-amyloidosis-related-cardiomyopathy/
  4. http://clinicaltrials.eu/trial/2023-507956-56-00/long-term-safety-study-of-ntla-2002-for-patients-with-hereditary-angioedema-using-messenger-rna-encoding-cas9-and-hu-g012267/
  5. http://clinicaltrials.eu/trial/2023-508138-33-00/study-on-the-safety-of-ntla-3001-for-adults-with-alpha-1-antitrypsin-deficiency-related-lung-disease/
  6. http://clinicaltrials.eu/trial/2024-511170-69-00/study-on-ntla-2001-for-patients-with-hereditary-transthyretin-amyloidosis-with-polyneuropathy/
  7. http://clinicaltrials.eu/trial/2024-512317-40-00/study-on-ntla-2002-for-adults-with-hereditary-angioedema-using-ziclumeran-and-lonvoguran/